Bleomycin electrosclerotherapy for vascular anomalies
Johansson T, Freundlinger N, Strohmaier C
Record ID 32018004894
Authors' objectives: Vascular anomalies are disorders of the endothelium that affect capillaries, arteries, veins, or the lymphatic system. The overall prevalence of vascular anomalies is approximately 4.5%, mostly due to haemangioma. This systematic review aimed to evaluate the evidence on the efficacy and safety of bleomycin electrosclerotherapy in patients with vascular anomalies compared with standard treatment.
Authors' results and conclusions: No evidence from controlled trials was available to evaluate efficacy. Regarding the safety of bleomycin electrosclerotherapy, serious adverse events are rare and other side effects are usually mild and self-limiting. A comparison with the safety profile of standard therapy was not possible due to the study designs of the included trials. The current evidence on bleomycin electrosclerotherapy is mainly based on prospective and retrospective single-arm case series with small sample sizes. The studies have a number of serious limitations.
Authors' recommendations: In summary, no clear conclusion can be drawn as to whether bleomycin electrosclerotherapy leads to better results than current treatment standards, as no robust comparative studies are available. Due to the methodological shortcomings of the available evidence and the lack of controlled evidence, the inclusion of bleomycin electrosclerotherapy in the catalogue of benefits is currently not recommended.
Project Status: Completed
Year Published: 2023
URL for published report: https://eprints.aihta.at/1456/1/DSD_137.pdf
URL for additional information: https://eprints.aihta.at/1456/
English language abstract: An English language summary is available
Publication Type: Full HTA
- Vascular Diseases
- Vascular Malformations
- Bleomycin electrosclerotherapy
- vascular anomalies
- vascular malformations
Organisation Name: Austrian Institute for Health Technology Assessment
Contact Address: Garnisongasse 7/20, A-1090 Vienna, Austria
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.